SEC Form 4 · accession 0001209191-19-003365
Principia Biopharma Inc. · PRNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simeon George
Director · 10% Owner
Period of report
Sep 13, 2018
Accepted (ET)
Jan 10, 2019 · 9:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510487
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $17.00 | Sep 13, 2018 | A | 20,475 | A | — | Sep 12, 2028 | Common Stock | 20,475 | 20,475 | D |
Explanation of responses
- F1The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. The stock option was granted to the Reporting Person as director's compensation. As a Vice President of S. R. One, Limited and an employee of GlaxoSmithKline LLC, the Reporting Person is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.